{"nctId":"NCT01070784","briefTitle":"A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan","startDateStruct":{"date":"2010-01"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":328,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Symbicort Turbuhaler (Budesonide/formoterol)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Drug: any available COPD treatment; investigator to decide"]}],"interventions":[{"name":"Symbicort Turbuhaler (Budesonide/formoterol)","otherNames":["Symbicort Turbuhaler"]},{"name":"Drug: any available COPD treatment; investigator to decide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A current clinical diagnosis of COPD according to the guidelines (GOLD, JPS)\n* Documented COPD symptoms for more than 2 years\n* Pre-bronchodilator FEV1â‰¦50% of predicted normal value, and post-bronchodilator FEV1/FVC\\<70%\n\nExclusion Criteria:\n\n* History and/or current clinical diagnosis of asthma and atopic diseases such as allergic rhinitis\n* Subjects with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator\n* COPD exacerbation during the run-in period or within 4 weeks prior to registration, requiring hospitalization and/or treatment with systemic steroids.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Erythrocytes","description":"Mean change from Baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"23.9"},{"groupId":"OG001","value":"-0.1","spread":"22.9"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Haemoglobin","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.74"},{"groupId":"OG001","value":"-0.05","spread":"0.75"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Leucocytes","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160.8","spread":"1704.0"},{"groupId":"OG001","value":"-184.8","spread":"1238.2"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Platelet Count","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"3.03"},{"groupId":"OG001","value":"0.12","spread":"4.04"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Eosinophils","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"2.68"},{"groupId":"OG001","value":"0.14","spread":"1.91"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Basophils","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.37"},{"groupId":"OG001","value":"-0.06","spread":"0.35"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Lymphocytes","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.47","spread":"6.56"},{"groupId":"OG001","value":"-3.24","spread":"7.00"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Monocytes","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"1.41"},{"groupId":"OG001","value":"-0.03","spread":"1.35"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Neutrophils","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.78","spread":"7.16"},{"groupId":"OG001","value":"2.92","spread":"7.64"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"7.6"},{"groupId":"OG001","value":"1.5","spread":"6.6"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"7.6"},{"groupId":"OG001","value":"1.1","spread":"6.5"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"38.4"},{"groupId":"OG001","value":"8.2","spread":"45.9"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Creatinine","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":"0.106"},{"groupId":"OG001","value":"-0.017","spread":"0.091"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.25"},{"groupId":"OG001","value":"0.00","spread":"0.18"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Sodium","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.0"},{"groupId":"OG001","value":"-0.6","spread":"1.7"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Potassium","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.34"},{"groupId":"OG001","value":"-0.08","spread":"0.37"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S- Calcium","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.34"},{"groupId":"OG001","value":"0.01","spread":"0.33"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Albumin","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.24"},{"groupId":"OG001","value":"0.04","spread":"0.26"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.35"},{"groupId":"OG001","value":"0.02","spread":"0.37"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.243","spread":"1.291"},{"groupId":"OG001","value":"0.224","spread":"1.423"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"4.09"},{"groupId":"OG001","value":"-0.64","spread":"3.32"}]}]}]},{"type":"PRIMARY","title":"Vital Signs- Sitting Systolic Blood Pressure(SBP)","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"16.2"},{"groupId":"OG001","value":"-3.2","spread":"15.0"}]}]}]},{"type":"PRIMARY","title":"Vital Signs- Sitting Diastolic Blood Pressure(DBP)","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"11.2"},{"groupId":"OG001","value":"-1.3","spread":"10.7"}]}]}]},{"type":"PRIMARY","title":"Vital Signs- Pulse Rate","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"11.1"},{"groupId":"OG001","value":"3.1","spread":"11.5"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - Heart Rate","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"11.4"},{"groupId":"OG001","value":"3.4","spread":"10.9"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - QT Interval","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"23.1"},{"groupId":"OG001","value":"-7.5","spread":"21.2"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - QTcB Interval","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"20.9"},{"groupId":"OG001","value":"2.4","spread":"22.6"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - QTcF Interval","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"16.3"},{"groupId":"OG001","value":"-1.1","spread":"17.4"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - RR Interval","description":"Change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.9","spread":"121.4"},{"groupId":"OG001","value":"-43.8","spread":"115.1"}]}]}]},{"type":"SECONDARY","title":"Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening","description":"There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.5"},{"groupId":"OG001","value":"-0.1","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness","description":"There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.7"},{"groupId":"OG001","value":"-0.1","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough","description":"There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.7"},{"groupId":"OG001","value":"-0.2","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic","description":"The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.25","spread":null},{"groupId":"OG001","value":"98.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic","description":"The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.51","spread":null},{"groupId":"OG001","value":"100.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First COPD Exacerbation","description":"A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"31.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations Over the Study Treatment Period","description":"A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Use","description":"The change from run-in period and daily during 52-week randomization treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.0"},{"groupId":"OG001","value":"0.0","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)","description":"The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.03","spread":"8.56"},{"groupId":"OG001","value":"-0.42","spread":"7.47"}]}]}]},{"type":"SECONDARY","title":"Morning Peak Expiratory Flow (PEF) Measured at Home","description":"The change from Run-in period average to 52-week randomization Treatment period average for each treatment group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"31.8"},{"groupId":"OG001","value":"5.7","spread":"30.9"}]}]}]},{"type":"SECONDARY","title":"Evening Peak Expiratory Flow (PEF) Measured at Home","description":"The change from Run-in period average to 52-week randomization Treatment period average for each treatment group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"30.0"},{"groupId":"OG001","value":"5.2","spread":"29.3"}]}]}]},{"type":"SECONDARY","title":"Morning FEV1 Measured by the Subjects at Home","description":"The change from run-in period and daily during 52-week randomization treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.017","spread":"0.147"},{"groupId":"OG001","value":"0.006","spread":"0.171"}]}]}]},{"type":"SECONDARY","title":"Evening FEV1 Measured by the Subjects at Home","description":"The change from run-in period and daily during 52-week randomization treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.142"},{"groupId":"OG001","value":"0.010","spread":"0.156"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":130},"commonTop":["Nasopharyngitis","Bronchitis","Constipation","Back Pain","Chronic Obstructive Pulmonary Disease"]}}}